View Item 

Show simple item record

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
dc.contributor.authorTerrault, Norah A.
dc.contributor.authorLok, Anna S.F.
dc.contributor.authorMcMahon, Brian J.
dc.contributor.authorChang, Kyong‐mi
dc.contributor.authorHwang, Jessica P.
dc.contributor.authorJonas, Maureen M.
dc.contributor.authorBrown, Robert S.
dc.contributor.authorBzowej, Natalie H.
dc.contributor.authorWong, John B.
dc.date.accessioned2018-04-04T18:48:37Z
dc.date.available2019-05-13T14:45:25Zen
dc.date.issued2018-04
dc.identifier.citationTerrault, Norah A.; Lok, Anna S.F.; McMahon, Brian J.; Chang, Kyong‐mi ; Hwang, Jessica P.; Jonas, Maureen M.; Brown, Robert S.; Bzowej, Natalie H.; Wong, John B. (2018). "Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance." Hepatology 67(4): 1560-1599.
dc.identifier.issn0270-9139
dc.identifier.issn1527-3350
dc.identifier.urihttps://hdl.handle.net/2027.42/142904
dc.publisherWiley Periodicals, Inc.
dc.publisherWorld Health Organization
dc.titleUpdate on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142904/1/hep29800.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142904/2/hep29800_am.pdf
dc.identifier.doi10.1002/hep.29800
dc.identifier.sourceHepatology
dc.identifier.citedreferenceMorisco F, Guarino M, La Bella S, Di Costanzo L, Caporaso N, Ayala F, Balato N. Lack of evidence of viral reactivation in HBsAgâ negative HBcAbâ positive and HCV patients undergoing immunosuppressive therapy for psoriasis. BMC Gastroenterol 2014; 14: 214.
dc.identifier.citedreferenceFox AN, Terrault NA. Individualizing hepatitis B infection prophylaxis in liver transplant recipients. J Hepatol 2011; 55: 507 â 509.
dc.identifier.citedreferenceRadhakrishnan K, Chi A, Quan D, Roberts J, Terrault N. Short Course of Postâ Operative Hepatitis B Immunoglobulin plus Antivirals Prevents Reinfection of Liver Transplant Recipients. Transplantation 2017; 101: 2079 â 2082.
dc.identifier.citedreferenceTeperman L, Spivey J, Poordad F, Schiano T, Bzowej N, Martin P, et al. Randomized Trial of Emtricitabine/Tenofovir DF Plus/Minus HBIG Withdrawal in Prevention of Chronic Hepatitis B Recurrence Postâ Liver Transplantation: 48 Week Results. Am J Transplant 2011; 11 ( Suppl 2 ): 48.
dc.identifier.citedreferenceFung J, Wong T, Chok K, Chan A, Cheung TT, Dai J, et al. Long Term Outcomes of Entecavir Monotherapy for Chronic Hepatitis B after Liver Transplantation: Results up to 8 years. Hepatology 2017; 66: 1036 â 1044.
dc.identifier.citedreferenceCoffin CS, Stock PG, Dove LM, Berg CL, Nissen NN, Curry MP, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIVâ HBV coinfected transplant recipients. Am J Transplant 2010; 10: 1268 â 1275.
dc.identifier.citedreferenceDe Simone P, Romagnoli R, Tandoi F, Carrai P, Ercolani G, Peri E, Zamboni F, et al. Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection: A Prospective, Multicenter Study. Transplantation 2016; 100: 1507 â 1512.
dc.identifier.citedreferenceYao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garciaâ Kennedy R, Gish RR. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999; 5: 491 â 496.
dc.identifier.citedreferenceCholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from antiâ hepatitis B core positive donors: a systematic review. J Hepatol 2010; 52: 272 â 279.
dc.identifier.citedreferencePerrillo R. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigenâ positive liver donation: a survey of North American, European, and Asianâ Pacific transplant programs. Liver Transpl 2009; 15: 223 â 232.
dc.identifier.citedreferenceOjo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931 â 940.
dc.identifier.citedreferenceLee J, Cho JH, Lee JS, Ahn DW, Kim CD, Ahn C, et al. Pretransplant Hepatitis B Viral Infection Increases Risk of Death After Kidney Transplantation: A Multicenter Cohort Study in Korea. Medicine (Baltimore) 2016; 95: e3671.
dc.identifier.citedreferenceFabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and survival after renal transplantation: metaâ analysis of observational studies. Am J Transplant 2005; 5: 2913 â 2921.
dc.identifier.citedreferenceChan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAgâ positive kidney allograft recipients. Hepatology 2002; 36: 1246 â 1252.
dc.identifier.citedreferenceYap DY, Tang CS, Yung S, Choy BY, Yuen MF, Chan TM. Longâ term outcome of renal transplant recipients with chronic hepatitis B infectionâ impact of antiviral treatments. Transplantation 2010; 90: 325 â 330.
dc.identifier.citedreferenceWachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, et al. The risk of transmission of hepatitis B from HBsAg(â ), HBcAb(+), HBIgM(â ) organ donors. Transplantation 1995; 59: 230 â 234.
dc.identifier.citedreferenceMahboobi N, Tabatabaei SV, Blum HE, Alavian SM. Renal grafts from antiâ hepatitis B coreâ positive donors: a quantitative review of the literature. Transpl Infect Dis 2012; 14: 445 â 451.
dc.identifier.citedreferenceSatterthwaite R, Ozgu I, Shidban H, Aswad S, Sunga V, Zapanta R, Jr., et al. Risks of transplanting kidneys from hepatitis B surface antigenâ negative, hepatitis B core antibodyâ positive donors. Transplantation 1997; 64: 432 â 435.
dc.identifier.citedreferenceOuseph R, Eng M, Ravindra K, Brock GN, Buell JF, Marvin MR. Review of the use of hepatitis B core antibodyâ positive kidney donors. Transplant Rev (Orlando) 2010; 24: 167 â 171.
dc.identifier.citedreferenceBussler S, Vogel M, Pietzner D, Harms K, Buzek T, Penke M, et al. New pediatric percentiles of liver enzyme serum levels (ALT, AST, GGT): Effects of age, sex, BMI and pubertal stage. Hepatology 2017 Sep 19. doi: 10.1002/hep.29542. [Epub ahead of print]
dc.identifier.citedreferencePoustchi H, George J, Esmaili S, Esnaâ Ashari F, Ardalan G, Sepanlou SG, Alavian SM. Gender differences in healthy ranges for serum alanine aminotransferase levels in adolescence. PLoS One 2011; 6: e21178.
dc.identifier.citedreferenceSchwimmer JB, Dunn W, Norman GJ, Pardee PE, Middleton MS, Kerkar N, Sirlin CB. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010; 138: 1357 â 1364, 1364.e1â 2.
dc.identifier.citedreferenceEngland K, Thorne C, Pembrey L, Tovo PA, Newell ML. Ageâ and sexâ related reference ranges of alanine aminotransferase levels in children: European paediatric HCV network. J Pediatr Gastroenterol Nutr 2009; 49: 71 â 77.
dc.identifier.citedreferenceTerrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63: 261 â 283.
dc.identifier.citedreferenceLok AS, McMahon BJ, Brown RS, Jr., Wong JB, Ahmed AT, Farah W, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and metaâ analysis. Hepatology 2016; 63: 284 â 306.
dc.identifier.citedreferenceJonas MM, Lok AS, McMahon BJ, Brown RS, Jr., Wong JB, Ahmed AT, et al. Antiviral therapy in management of chronic hepatitis B viral infection in children: a systematic review and metaâ analysis. Hepatology 2016; 63: 307 â 318.
dc.identifier.citedreferenceBrown RS, Jr., McMahon BJ, Lok AS, Wong JB, Ahmed AT, Mouchli MA, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and metaâ analysis. Hepatology 2016; 63: 319 â 333.
dc.identifier.citedreferenceWorld Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva, Switzerland: World Health Organization; 2015.
dc.identifier.citedreferenceAgarwal K, Fung S, Seto WK, Lim Y, Gane E, Janssen H, et al. A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAgâ positive, chronic hepatitis B: efficacy and safety results at week 96. J Hepatol 2017; 66 ( Suppl 1 ): S478.
dc.identifier.citedreferenceBrunetto M, Lim YS, Gane E, Seto WK, Osipenko M, Ahn SH, et al. A Phase 3 Study Comparing Tenofovir Alafenamide (TAF) to Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAgâ Negative, Chronic Hepatitis B (CHB): Efficacy and Safety Results at Week 96. J Hepatol 2017; 152 ( Suppl 1 ): S1086.
dc.identifier.citedreferenceHeathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Threeâ year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132 â 143.
dc.identifier.citedreferenceLau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfaâ 2a, lamivudine, and the combination for HBeAgâ positive chronic hepatitis B. N Engl J Med. 2005; 352: 2682 â 2695.
dc.identifier.citedreferenceLiaw YF, Jia JD, Chan HL, Han KH, Tanwandee T, Chuang WL, et al. Shorter durations and lower doses of peginterferon alfaâ 2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011; 54: 1591 â 1599.
dc.identifier.citedreferenceJanssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfaâ 2b alone or in combination with lamivudine for HBeAgâ positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123 â 129.
dc.identifier.citedreferenceBuster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after longâ term followâ up of HBeAgâ positive patients treated with peginterferon alphaâ 2b. Gastroenterology 2008; 135: 459 â 467.
dc.identifier.citedreferenceLok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ideâ naïve patients with chronic hepatitis B. Gastroenterology 2012; 143: 619 â 628.e1.
dc.identifier.citedreferenceGish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAgâ positive chronic hepatitis B. Gastroenterology 2007; 133: 1437 â 1444.
dc.identifier.citedreferenceMarcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442 â 2455.
dc.identifier.citedreferenceLai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAgâ negative chronic hepatitis B. N Engl J Med 2006; 354: 1011 â 1020.
dc.identifier.citedreferenceChan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAgâ positive chronic hepatitis B virus infection: a randomised, doubleâ blind, phase 3, nonâ inferiority trial. Lancet Gastroenterol Hepatol 2016; 1: 185 â 195.
dc.identifier.citedreferenceButi M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAgâ negative chronic hepatitis B virus infection: a randomised, doubleâ blind, phase 3, nonâ inferiority trial. Lancet Gastroenterol Hepatol 2016; 1: 196 â 206.
dc.identifier.citedreferenceArribas JR, Thompson M, Sax PE, Haas B, McDonald C, Wohl DA, et al. Brief Report: Randomized, Doubleâ Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIVâ 1 Treatment: Week 144 Results. J Acquir Immune Defic Syndr 2017; 75: 211 â 218.
dc.identifier.citedreferenceRaffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, et al. Brief Report: Longâ term (96â week) Efficacy and Safety After Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) in HIVâ infected, Virologically Suppressed Adults. J Acquir Immune Defic Syndr 2017; 75: 226 â 231.
dc.identifier.citedreferenceLavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97 â 107.
dc.identifier.citedreferenceNelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease. Clin Liver Dis 2016; 20: 607 â 628.
dc.identifier.citedreferenceWeinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57: 1 â 20.
dc.identifier.citedreferenceMast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54: 1 â 31.
dc.identifier.citedreferencePetersen NJ, Barrett DH, Bond WW, Berquist KR, Favero MS, Bender TR, Maynard JE. Hepatitis B surface antigen in saliva, impetiginous lesions, and the environment in two remote Alaskan villages. Appl Environ Microbiol 1976; 32: 572 â 574.
dc.identifier.citedreferenceGhany MG, Perrillo R, Li R, Belle SH, Janssen HL, Terrault NA, et al. Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype. Clin Gastroenterol Hepatol 2015; 13: 183 â 192.
dc.identifier.citedreferenceSchwarz KB, Cloonan YK, Ling SC, Murray KF, Rodriguezâ Baez N, Schwarzenberg SJ, et al. Children with Chronic Hepatitis B in the United States and Canada. J Pediatr 2015; 167: 1287 â 1294.e2.
dc.identifier.citedreferenceBond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B virus after drying and storage for one week. Lancet 1981; 1: 550 â 551.
dc.identifier.citedreferenceBeasley RP, Huang LY. Postnatal infectivity of hepatitis B surface antigenâ carrier mothers. J Infect Dis 1983; 147: 185 â 190.
dc.identifier.citedreferenceBeasley RP, Hwang LY, Lin CC, Leu ML, Stevens CE, Szmuness W, Chen KP. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 1982; 146: 198 â 204.
dc.identifier.citedreferenceCoursaget P, Yvonnet B, Chotard J, Vincelot P, Sarr M, Diouf C, Chiron JP, et al. Ageâ and sexâ related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J Med Virol 1987; 22: 1 â 5.
dc.identifier.citedreferenceMcMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, Maynard JE. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151: 599 â 603.
dc.identifier.citedreferenceTassopoulos NC, Papaevangelou GJ, Roumeliotouâ Karayannis A, Ticehurst JR, Feinstone SM, Purcell RH. Detection of hepatitis B virus DNA in asymptomatic hepatitis B surface antigen carriers: relation to sexual transmission. Am J Epidemiol 1987; 126: 587 â 591.
dc.identifier.citedreferenceBodsworth N, Cooper D, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991; 163: 1138 â 1140.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011; 60: 1709 â 1711.
dc.identifier.citedreferenceDivision of Viral Hepatitis and National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention. Hepatitis B FAQs for Health Professionals. Atlanta, GA: Centers for Disease Control and Prevention; 2016.
dc.identifier.citedreferenceRaimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160 â 170.
dc.identifier.citedreferenceLok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661 â 662.
dc.identifier.citedreferenceGounder PP, Bulkow LR, McMahon BJ. Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinomaâ authorsâ reply. Aliment Pharmacol Ther 2016; 44: 650 â 651.
dc.identifier.citedreferenceLiu J, Yang HI, Lee MH, Lu SN, Jen CL, Batrlaâ Utermann R, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut 2014; 63: 1648 â 1657.
dc.identifier.citedreferenceNathanson MH, Terrault N. Hepatitis B surface antigen loss: not all that we hoped it would be. Hepatology 2016; 64: 328 â 329.
dc.identifier.citedreferenceGandhi RT, Wurcel A, McGovern B, Lee H, Shopis J, Corcoran CP, et al. Low prevalence of ongoing hepatitis B viremia in HIVâ positive individuals with isolated antibody to hepatitis B core antigen. J Acquir Immune Defic Syndr 2003; 34: 439 â 441.
dc.identifier.citedreferenceIkeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, et al. Antibody to hepatitis B core antigen and risk for hepatitis Câ related hepatocellular carcinoma: a prospective study. Ann Intern Med 2007; 146: 649 â 656.
dc.identifier.citedreferenceLok AS, Lai CL, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs. Hepatology 1988; 8: 766 â 770.
dc.identifier.citedreferenceMcMahon BJ, Parkinson AJ, Helminiak C, Wainwright RB, Bulkow L, Kellermanâ Douglas A, et al. Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen. Gastroenterology 1992; 103: 590 â 594.
dc.identifier.citedreferenceAbbot Laboratories. Hepatitis B Virus Core Antigen (E. coli, Recombinant). Silver Spring, MD: Food and Drug Administration; 2002.
dc.identifier.citedreferenceU.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Requalification Method for Reentry of Blood Donors Deferred Because of Reactive Test Results for Antibody to Hepatitis B Core Antigen (Antiâ HBc). In: Guidance for Industry. Rockville, MD: Office of Communication, Outreach and Development; 2010.
dc.identifier.citedreferencePaul S, Dickstein A, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a metaâ analysis. Hepatology 2017; 66: 379 â 388.
dc.identifier.citedreferenceLok AS, Lai CL, Wu PC, Leung EK. Longâ term followâ up in a randomised controlled trial of recombinant alpha 2â interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; 2:298 â 302.
dc.identifier.citedreferenceGandhi RT, Wurcel A, Lee H, McGovern B, Shopis J, Geary M, et al. Response to hepatitis B vaccine in HIVâ 1â positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005; 191: 1435 â 1441.
dc.identifier.citedreferencePiroth L, Launay O, Michel ML, Bourredjem A, Miailhes P, Ajana F, et al. Vaccination Against Hepatitis B Virus (HBV) in HIVâ 1â Infected Patients With Isolated Antiâ HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study. J Infect Dis 2016; 213: 1735 â 1742.
dc.identifier.citedreferenceOnozawa M, Hashino S, Darmanin S, Okada K, Morita R, Takahata M, et al. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant 2008; 14: 1226 â 1230.
dc.identifier.citedreferenceTakahata M, Hashino S, Onozawa M, Shigematsu A, Sugita J, Fujimoto K, et al. Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in nonâ responders to hepatitis B vaccine after allogeneic stem cell transplantation: longâ term analysis of intervention in RS with vaccine for patients with previous HBV infection. Transplant Infect Dis 2014; 16: 797 â 801.
dc.identifier.citedreferenceWong GL, Chan HL, Yu Z, Chan AW, Choi PC, Chim AM, Chan HY, et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis Bâ a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther 2014; 39: 883 â 893.
dc.identifier.citedreferenceChan AW, Wong GL, Chan HY, Tong JH, Yu YH, Choi PC, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol 2017; 32: 667 â 676.
dc.identifier.citedreferenceVilla E, Rubbiani L, Barchi T, Ferretti I, Grisendi A, De Palma M, et al. Susceptibility of chronic symptomless HBsAg carriers to ethanolâ induced hepatic damage. Lancet 1982; 2 ( 8310 ): 1243 â 1244.
dc.identifier.citedreferenceChevillotte G, Durbec JP, Gerolami A, Berthezene P, Bidart JM, Camatte R. Interaction between hepatitis b virus and alcohol consumption in liver cirrhosis. An epidemiologic study. Gastroenterology 1983; 85: 141 â 145.
dc.identifier.citedreferenceTanaka K, Hirohata T, Takeshita S, Hirohata I, Koga S, Sugimachi K, et al. Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: a caseâ control study in Fukuoka, Japan. Int J Cancer 1992; 51: 509 â 514.
dc.identifier.citedreferenceAustin H, Delzell E, Grufferman S, Levine R, Morrison AS, Stolley PD, Cole P. A caseâ control study of hepatocellular carcinoma and the hepatitis B virus, cigarette smoking, and alcohol consumption. Cancer Res 1986; 46: 962 â 966.
dc.identifier.citedreferenceVilla E, Rubbiani L, Barchi T, Ferretti I, Grisendi A, De Palma M, et al. Susceptibility of chronic symptomless HBsAg carriers to ethanolâ induced hepatic damage. Lancet 1982; 2: 1243 â 1244.
dc.identifier.citedreferenceAdvisory Committee on Immunization P, Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55: 1 â 23.
dc.identifier.citedreferenceHarpaz R, Seidlein LV, Averhoff FM, Tormey MP, Sinha SD, Kotsopoulou K, et al. Transmission of hepatitis B to multiple patients from a surgeon without evidence of inadequate infection control. N Engl J Med 1996; 334: 549 â 554.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Updated CDC recommendations for the management of hepatitis B virusâ infected healthâ care providers and students. MMWR Recomm Rep 2012; 61: 1 â 12.
dc.identifier.citedreferenceMast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55: 1 â 33; quiz, CE31â CE34.
dc.identifier.citedreferenceSamadi Kochaksaraei G, Castillo E, Osman M, Simmonds K, Scott AN, Oshiomogho JI, et al. Clinical course of 161 untreated and tenofovirâ treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region. J Viral Hepat 2016; 23: 15 â 22.
dc.identifier.citedreferenceChang CY, Aziz N, Poongkunran M, Javaid A, Trinh HN, Lau D, Nguyen MH. Serum Alanine Aminotransferase and Hepatitis B DNA Flares in Pregnant and Postpartum Women with Chronic Hepatitis B. Am J Gastroenterol 2016; 111: 1410 â 1415.
dc.identifier.citedreferenceChang CY, Aziz N, Poongkunran M, Javaid A, Trinh HN, Lau DT, Nguyen MH. Serum Aminotransferase Flares in Pregnant and Postpartum Women With Current or Prior Treatment for Chronic Hepatitis B. J Clin Gastroenterol 2018; 52: 255 â 261.
dc.identifier.citedreferenceNguyen V, Tan PK, Greenup AJ, Glass A, Davison S, Samarasinghe D, et al. Antiâ viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against postâ partum flare. Aliment Pharmacol Ther 2014; 39: 1225 â 1234.
dc.identifier.citedreferencePan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. N Engl J Med 2016; 374: 2324 â 2334.
dc.identifier.citedreferenceChen HL, Lee CN, Chang CH, Ni YH, Shyu MK, Chen SM, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting motherâ toâ infant transmission of hepatitis B virus. Hepatology 2015; 62: 375 â 386.
dc.identifier.citedreferenceJacobson DL, Patel K, Williams PL, Geffner ME, Siberry GK, DiMeglio LA, et al. Growth at 2 Years of Age in HIVâ exposed Uninfected Children in the United States by Trimester of Maternal Antiretroviral Initiation. Pediatr Infect Dis J 2017; 36: 189 â 197.
dc.identifier.citedreferenceJao J, Abrams EJ, Phillips T, Petro G, Zerbe A, Myer L. In Utero Tenofovir Exposure Is not Associated With Fetal Long Bone Growth. Clin Infect Dis 2016; 62: 1604 â 1609.
dc.identifier.citedreferenceNachega JB, Uthman OA, Mofenson LM, Anderson JR, Kanters S, Renaud F, et al. Safety of Tenofovir Disoproxil Fumarateâ Based Antiretroviral Therapy Regimens in Pregnancy for HIVâ Infected Women and Their Infants: A Systematic Review and Metaâ Analysis. J Acquir Immune Defic Syndr 2017; 76: 1 â 12.
dc.identifier.citedreferenceSiberry GK, Jacobson DL, Kalkwarf HJ, Wu JW, DiMeglio LA, Yogev R, et al. Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy. Clin Infect Dis 2015; 61: 996 â 1003.
dc.identifier.citedreferenceAlexander JM, Ramus R, Jackson G, Sercely B, Wendel GD, Jr. Risk of hepatitis B transmission after amniocentesis in chronic hepatitis B carriers. Infect Dis Obstet Gynecol 1999; 7: 283 â 286.
dc.identifier.citedreferenceYi W, Pan CQ, Hao J, Hu Y, Liu M, Li L, Liang D. Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigenâ positive mothers. J Hepatol 2014; 60: 523 â 529.
dc.identifier.citedreferenceBenaboud S, Pruvost A, Coffie PA, Ekouevi DK, Urien S, Arrive E, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIVâ 1â infected women in Abidjan, Cote d’Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents Chemother 2011; 55: 1315 â 1317.
dc.identifier.citedreferenceMirochnick M, Taha T, Kreitchmann R, Nielsenâ Saines K, Kumwenda N, Joao E, et al. Pharmacokinetics and safety of tenofovir in HIVâ infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr 2014; 65: 33 â 41.
dc.identifier.citedreferenceGupta I, Ratho RK. Immunogenicity and safety of two schedules of Hepatitis B vaccination during pregnancy. J Obstet Gynaecol Res 2003; 29: 84 â 86.
dc.identifier.citedreferenceLevy M, Koren G. Hepatitis B vaccine in pregnancy: maternal and fetal safety. Am J Perinatol 1991; 8: 227 â 232.
dc.identifier.citedreferenceSheffield JS, Hickman A, Tang J, Moss K, Kourosh A, Crawford NM, Wendel GD, Jr. Efficacy of an accelerated hepatitis B vaccination program during pregnancy. Obstet Gynecol 2011; 117: 1130 â 1135.
dc.identifier.citedreferenceKim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017; 66: 136 â 138.
dc.identifier.citedreferenceFitzSimons D, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Milan, Italy, 17â 18 November 2011. Vaccine 2013; 31: 584 â 590.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Epidemiology and Prevention of Vaccineâ Preventable Diseases 13th Edition. In: Hamborsky J, Kroger A, Wolfe S, eds. The Pink Book. Washington, DC: Public Health Foundation; 2015: 157 â 174.
dc.identifier.citedreferenceAggeletopoulou I, Davoulou P, Konstantakis C, Thomopoulos K, Triantos C. Response to hepatitis B vaccination in patients with liver cirrhosis. Rev Med Virol 2017: 27: 1 â 8.
dc.identifier.citedreferenceRubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58: 309 â 318.
dc.identifier.citedreferenceRey D, Piroth L, Wendling MJ, Miailhes P, Michel ML, Dufour C, et al. Safety and immunogenicity of doubleâ dose versus standardâ dose hepatitis B revaccination in nonâ responding adults with HIVâ 1 (ANRS HB04 Bâ BOOST): a multicentre, openâ label, randomised controlled trial. Lancet Infect Dis 2015; 15: 1283 â 1291.
dc.identifier.citedreferenceSchillie SF, Murphy TV. Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review. Vaccine 2013; 31: 2506 â 2516.
dc.identifier.citedreferenceSchillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep 2018; 67 (No. RR-1): 1 â 31.
dc.identifier.citedreferenceCenter for Disease Control and Prevention. Notice to Readers: FDA Approval of an Alternate Dosing Schedule for a Combined Hepatitis A and B Vaccine (Twinrix). MMWR Morb Mortal Wkly Rep 2007; 56: 1057.
dc.identifier.citedreferenceLeise MD, Talwalkar JA. Immunizations in chronic liver disease: what should be done and what is the evidence. Curr Gastroenterol Rep 2013; 15: 300.
dc.identifier.citedreferenceTan A, Koh S, Bertoletti A. Immune Response in Hepatitis B Virus Infection. Cold Spring Harb Perspect Med 2015; 5: a021428.
dc.identifier.citedreferenceBengsch B, Chang KM. Evolution in Our Understanding of Hepatitis B Virus Virology and Immunology. Clin Liver Dis 2016; 20: 629 â 644.
dc.identifier.citedreferenceLee JK, Shim JH, Lee HC, Lee SH, Kim KM, Lim YS, et al. Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology 2010; 51: 1577 â 1583.
dc.identifier.citedreferenceRuhl CE, Everhart JE. Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology 2012; 55: 447 â 454.
dc.identifier.citedreferencePrati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1 â 10.
dc.identifier.citedreferenceDutta A, Saha C, Johnson CS, Chalasani N. Variability in the upper limit of normal for serum alanine aminotransferase levels: a statewide study. Hepatology 2009; 50: 1957 â 1962.
dc.identifier.citedreferenceNeuschwanderâ Tetri BA, Unalp A, Creer MH; Nonalcoholic Steatohepatitis Clinical Research Network. Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels. Arch Intern Med 2008; 168: 663 â 666.
dc.identifier.citedreferenceAllice T, Cerutti F, Pittaluga F, Varetto S, Gabella S, Marzano A, et al. COBAS AmpliPrepâ COBAS TaqMan hepatitis B virus (HBV) test: a novel automated realâ time PCR assay for quantification of HBV DNA in plasma. J Clin Microbiol 2007; 45: 828 â 834.
dc.identifier.citedreferenceChu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002; 36: 1408 â 1415.
dc.identifier.citedreferenceHoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056 â 1075.
dc.identifier.citedreferenceChen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang L, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liverâ related death. Gastroenterology 2010; 138: 1747 â 1754.
dc.identifier.citedreferenceLin CL, Kao JH. Natural history of acute and chronic hepatitis B: the role of HBV genotypes and mutants. Best Pract Res Clin Gastroenterol 2017; 31: 249 â 255.
dc.identifier.citedreferenceShi W, Zhang Z, Ling C, Zheng W, Zhu C, Carr MJ, Higgins DG. Hepatitis B virus subgenotyping: history, effects of recombination, misclassifications, and corrections. Infect Genet Evol 2013; 16: 355 â 361.
dc.identifier.citedreferenceMarcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, et al. Combination of Tenofovir Disoproxil Fumarate and Peginterferon alphaâ 2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. Gastroenterology 2016; 150: 134 â 1 44.e10.
dc.identifier.citedreferenceBuster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL. Factors that predict response of patients with hepatitis B e antigenâ positive chronic hepatitis B to peginterferonâ alfa. Gastroenterology 2009; 137: 2002 â 2009.
dc.identifier.citedreferenceAhn SH, Park YN, Park JY, Chang HY, Lee JM, Shin JE, et al. Longâ term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005; 42: 188 â 194.
dc.identifier.citedreferenceLivingston SE, Simonetti JP, McMahon BJ, Bulkow LR, Hurlburt KJ, Homan CE, et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis 2007; 195: 5 â 11.
dc.identifier.citedreferenceChing LK, Gounder PP, Bulkow L, Spradling PR, Bruce MG, Negus S, et al. Incidence of hepatocellular carcinoma according to hepatitis B virus genotype in Alaska Native people. Liver Int 2016; 36: 1507 â 1515.
dc.identifier.citedreferenceCornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HL, Chan HL. The role of quantitative hepatitis B surface antigen revisited. J Hepatol 2017; 66: 398 â 411.
dc.identifier.citedreferenceZeng DW, Zhang JM, Liu YR, Dong J, Jiang JJ, Zhu YY. A Retrospective Study on the Significance of Liver Biopsy and Hepatitis B Surface Antigen in Chronic Hepatitis B Infection. Medicine (Baltimore) 2016; 95: e2503.
dc.identifier.citedreferenceWang L, Zou ZQ, Wang K, Yu JG, Liu XZ. Role of serum hepatitis B virus marker quantitation to differentiate natural history phases of HBV infection. Hepatol Int 2016; 10: 133 â 138.
dc.identifier.citedreferenceBrouwer WP, Chan HL, Brunetto MR, Martinotâ Peignoux M, Arends P, Cornberg M, et al. Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Longâ term Followâ up. Clin Gastroenterol Hepatol 2016; 14: 1481 â 1489.e5.
dc.identifier.citedreferenceTseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol 2013; 48: 13 â 21.
dc.identifier.citedreferenceLok AS, Ganovaâ Raeva L, Cloonan Y, Punkova L, Lin HS, Lee WM, et al. Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment. J Viral Hepat 2017; 24: 1032 â 1042.
dc.identifier.citedreferenceKim JH, Park YK, Park ES, Kim KH. Molecular diagnosis and treatment of drugâ resistant hepatitis B virus. World J Gastroenterol 2014; 20: 5708 â 5720.
dc.identifier.citedreferenceLiaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, Changâ Chien CS. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983; 84: 216 â 219.
dc.identifier.citedreferenceLiaw YF, Pao CC, Chu CM, Sheen IS, Huang MJ. Changes of serum hepatitis B virus DNA in two types of clinical events preceding spontaneous hepatitis B e antigen seroconversion in chronic type B hepatitis. Hepatology 1987; 7: 1 â 3.
dc.identifier.citedreferenceLok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92: 1839 â 1843.
dc.identifier.citedreferenceLok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol 1990; 10: 29 â 34.
dc.identifier.citedreferenceChu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat 2007; 14: 147 â 152.
dc.identifier.citedreferenceCheng J, Hou J, Ding H, Chen G, Xie Q, Wang Y, et al. Validation of Ten Noninvasive Diagnostic Models for Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B. PLoS One 2015; 10: e0144425.
dc.identifier.citedreferenceJia J, Hou J, Ding H, Chen G, Xie Q, Wang Y, et al. Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2015; 30: 756 â 762.
dc.identifier.citedreferenceSingh S, Muir AJ, Dieterich DT, Falckâ Ytter YT. American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. Gastroenterology 2017; 152: 1544 â 1577.
dc.identifier.citedreferenceXiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosisâ 4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and metaâ analysis. Hepatology 2015; 61: 292 â 302.
dc.identifier.citedreferenceBrunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, Bonino F. Outcome of antiâ HBe positive chronic hepatitis B in alphaâ interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263 â 270.
dc.identifier.citedreferenceChan HL, Thompson A, Martinotâ Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011â a core group report. J Hepatol 2011; 55: 1121 â 1131.
dc.identifier.citedreferenceLiu J, Yang HI, Lee MH, Jen CL, Batrlaâ Utermann R, Lu SN, et al. Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression. Hepatology 2016; 64: 381 â 389.
dc.identifier.citedreferenceLiaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991; 13: 627 â 631.
dc.identifier.citedreferenceChu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a longâ term followâ up. Hepatology 2007; 45: 1187 â 1192.
dc.identifier.citedreferenceYip TC, Chan HL, Wong VW, Tse YK, Lam KL, Wong GL. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Hepatol 2017; 67: 902 â 908.
dc.identifier.citedreferenceChen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123: 1084 â 1089.
dc.identifier.citedreferenceHeimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67: 358 â 380.
dc.identifier.citedreferenceBruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208 â 1236.
dc.identifier.citedreferenceChayanupatkul M, Omino R, Mittal S, Kramer JR, Richardson P, Thrift AP, et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol 2017; 66: 355 â 362.
dc.identifier.citedreferenceYu MW, Lin CL, Liu CJ, Yang SH, Tseng YL, Wu CF. Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liverâ Related Death in Men With Chronic Hepatitis B: A Large Cohort Study. Gastroenterology 2017; 153: 1006 â 1017.e5.
dc.identifier.citedreferenceHuang YT, Yang HI, Liu J, Lee MH, Freeman JR, Chen CJ. Mediation Analysis of Hepatitis B and C in Relation to Hepatocellular Carcinoma Risk. Epidemiology 2016; 27: 14 â 20.
dc.identifier.citedreferenceIoannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 2013; 57: 249 â 257.
dc.identifier.citedreferenceFattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127(5Suppl1): S35 â S50.
dc.identifier.citedreferenceAmerican Association for the Study of Liver Diseases, Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. http://www.hcvguidelines.org/full-report/hcv-testing-and-linkage-care. Updated April 27, 2017. Accessed January 11, 2018.
dc.identifier.citedreferenceKim YJ, Lee JW, Kim YS, Jeong SH, Kim YS, Yim HJ, et al. Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus. Korean J Hepatol 2011; 17: 199 â 205.
dc.identifier.citedreferenceUyanikoglu A, Akyuz F, Baran B, Simsek BP, Ermis F, Demir K, et al. Coâ infection with hepatitis B does not alter treatment response in chronic hepatitis C. Clin Res Hepatol Gastroenterol 2013; 37: 485 â 490.
dc.identifier.citedreferenceLiu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, et al. Peginterferon Alfaâ 2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses. Gastroenterology 2008; 136: 496 â 504.e3.
dc.identifier.citedreferencePotthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, et al. The HEPâ NET B/C coâ infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferonâ alpha2b and ribavirin in patients with HBV/HCV coâ infection. J Hepatol 2008; 49: 688 â 694.
dc.identifier.citedreferenceWang C, Ji D, Chen J, Shao Q, Li B, Liu J, et al. Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Directâ acting Antiviral Agents. Clin Gastroenterol Hepatol 2017; 15: 132 â 136.
dc.identifier.citedreferenceBersoffâ Matcha SJ, Cao K, Jason M, Ajao A, Jones SC, Meyer T, Brinker A. Hepatitis B Virus Reactivation Associated With Directâ Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann Intern Med 2017; 166: 792 â 798.
dc.identifier.citedreferenceBelperio PS, Shahoumian TA, Mole LA, Backus LI. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology 2017; 66: 27 â 36.
dc.identifier.citedreferenceChen G, Wang C, Chen J, Ji D, Wang Y, Wu V, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and metaâ analysis. Hepatology 2017; 66: 13 â 26.
dc.identifier.citedreferenceAbbas Z, Jafri W, Raza S. Hepatitis D: Scenario in the Asiaâ Pacific region. World Journal of Gastroenterology 2010; 16: 554 â 562.
dc.identifier.citedreferenceWorld Health Organization. Hepatitis D: Fact Sheet. In: Media Centre. Geneva, Switzerland; World Health Organization; 2017.
dc.identifier.citedreferenceChow SK, Atienza EE, Cook L, Prince H, Slev P, Lapeâ Nixon M, Jerome KR. Comparison of Enzyme Immunoassays for Detection of Antibodies to Hepatitis D Virus in Serum. Clin Vaccine Immunol 2016; 23: 732 â 734.
dc.identifier.citedreferenceCastelnau C, Le Gal F, Ripault M, Gordien E, Martinotâ Peignoux M, Boyer N, et al. Efficacy of peginterferon alfaâ 2b in chronic delta hepatitis.Relevance of quantitative RTâ PCR for followâ up. Hepatology 2006; 44: 728 â 735.
dc.identifier.citedreferenceWedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364: 322 â 331.
dc.identifier.citedreferenceAbbas Z, Memon MS, Mithani H, Jafri W, Hamid S. Treatment of chronic hepatitis D patients with pegylated interferon: a realâ world experience. Antivir Ther 2014; 19: 463 â 468.
dc.identifier.citedreferenceHeidrich B, Yurdaydin C, Kabacam G, Ratsch BA, Zachou K, Bremer B, et al. Late HDV RNA relapse after peginterferon alphaâ based therapy of chronic hepatitis delta. Hepatology 2014; 60: 87 â 97.
dc.identifier.citedreferenceHeller T, Rotman Y, Koh C, Clark S, Haynesâ Williams V, Chang R, et al. Longâ term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther 2014; 40: 93 â 104.
dc.identifier.citedreferenceKeskin O, Wedemeyer H, Tuzun A, Zachou K, Deda X, Dalekos GN, et al. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. Clin Gastroenterol Hepatol 2015; 13: 2342 â 2349.e1â 2.
dc.identifier.citedreferenceBogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J Hepatol 2016; 65: 490 â 498.
dc.identifier.citedreferenceKoh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynesâ Williams V, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proofâ ofâ concept randomised, doubleâ blind, placeboâ controlled phase 2A trial. Lancet Infect Dis 2015; 15: 1167 â 1174.
dc.identifier.citedreferenceDore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapyâ naive and â experienced patients coinfected with HIVâ 1 and hepatitis B virus. J Infect Dis 2004; 189: 1185 â 1192.
dc.identifier.citedreferenceHoff J, Baniâ Sadr F, Gassin M, Raffi F. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of antiâ human immunodeficiency virus regimens. Clin Infect Dis 2001; 32: 963 â 969.
dc.identifier.citedreferenceBenhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Longâ term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virusâ infected patients. Hepatology 1999; 30: 1302 â 1306.
dc.identifier.citedreferencePanel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIVâ 1â Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2016.
dc.identifier.citedreferenceGallant J, Brunetta J, Crofoot G, Benson P, Mills A, Brinson C, et al. Brief Report: Efficacy and Safety of Switching to a Singleâ Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIVâ 1/Hepatitis Bâ Coinfected Adults. J Acquir Immune Defic Syndr 2016; 73: 294 â 298.
dc.identifier.citedreferenceGallant JE, Daar ES, Raffi F, Brinson C, Ruane P, DeJesus E, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixedâ dose combinations containing emtricitabine as backbones for treatment of HIVâ 1 infection in virologically suppressed adults: a randomised, doubleâ blind, activeâ controlled phase 3 trial. Lancet HIV 2016; 3: e158 â e165.
dc.identifier.citedreferenceHuhn GD, Tebas P, Gallant J, Wilkin T, Cheng A, Yan M, et al. A Randomized, Openâ Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatmentâ Experienced HIVâ 1â Infected Adults. J Acquir Immune Defic Syndr 2017; 74: 193 â 200.
dc.identifier.citedreferenceMcMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Windâ Rotolo M, et al. The HBV drug entecavirâ effects on HIVâ 1 replication and resistance. N Engl J Med 2007; 356: 2614 â 2621.
dc.identifier.citedreferenceManegold C, Hannoun C, Wywiol A, Dietrich M, Polywka S, Chiwakata CB, Gunther S. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001; 32: 144 â 148.
dc.identifier.citedreferenceSulkowski MS, Thomas D, Chaisson R, Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immumodeficiency virus and the role of hepatitis C and B virus infection. JAMA 2000; 283: 74 â 80.
dc.identifier.citedreferenceden Brinker M, Wit FW, Wertheimâ van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, et al. Hepatitis B and C virus coâ infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIVâ 1 infection. AIDS 2000; 14: 2895 â 2902.
dc.identifier.citedreferenceLok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182 â 188.
dc.identifier.citedreferenceYeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299 â 307.
dc.identifier.citedreferenceYeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004; 15: 1661 â 1666.
dc.identifier.citedreferenceJang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemoâ lipiodolization. Hepatology 2006; 43: 233 â 240.
dc.identifier.citedreferenceHui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAgâ negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59 â 68.
dc.identifier.citedreferenceHsiao LT, Chiou TJ, Liu JH, Chu CJ, Lin YC, Chao TC, et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006; 12: 84 â 94.
dc.identifier.citedreferenceLoomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519 â 528.
dc.identifier.citedreferencePaul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Metaâ analysis. Ann Intern Med 2016; 164: 30 â 40.
dc.identifier.citedreferenceLau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742 â 1749.
dc.identifier.citedreferenceHuang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD. Randomized controlled trial of entecavir prophylaxis for rituximabâ associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765 â 2772.
dc.identifier.citedreferenceLee YH, Bae SC, Song GG. Hepatitis B virus reactivation in HBsAgâ positive patients with rheumatic diseases undergoing antiâ tumor necrosis factor therapy or DMARDs. Int J Rheum Dis 2013; 16: 527 â 531.
dc.identifier.citedreferenceMori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol 2015; 21: 10274 â 10289.
dc.identifier.citedreferenceKanaan N, Kabamba B, Maréchal C, Pirson Y, Beguin C, Goffin E, Hassoun Z. Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection. J Clin Virol 2012; 55: 233 â 238.
dc.identifier.citedreferenceOnozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, et al. Progressive disappearance of antiâ hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005; 79: 616 â 619.
dc.identifier.citedreferenceHammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1049 â 1059.
dc.identifier.citedreferenceEuropean Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167 â 185.
dc.identifier.citedreferenceSarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asianâ Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10: 1 â 98.
dc.identifier.citedreferenceHwang JP, Fisch MJ, Zhang H, Kallen MA, Routbort MJ, Lal LS, et al. Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract 2012; 8: e32 â e39.
dc.identifier.citedreferenceHwang JP, Fisch MJ, Lok AS, Zhang H, Vierling JM, Suarezâ Almazor ME. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer 2013; 13: 534.
dc.identifier.citedreferenceVisram A, Chan KK, McGee P, Boro J, Hicks LK, Feld JJ. Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than riskâ based screening. PLoS One 2015; 10: e0120749.
dc.identifier.citedreferenceHwang JP, Lok A, Fisch MJ, Cantor SB, Barbo AG, Lin HY, et al. Models to Predict Hepatitis B Virus Infection among Patients with Cancer Undergoing Systemic Antiâ cancer Therapy: A Prospective Cohort Study. In: Society of General Internal Medicine Annual Meeting, Washington, DC, 2017.
dc.identifier.citedreferencePerrillo RP, Gish R, Falckâ Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 221 â 244.e3.
dc.identifier.citedreferenceVoican CS, Mir O, Loulergue P, Dhooge M, Brezault C, Dréanic J, et al. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Ann Oncol 2016; 27: 2172 â 2184.
dc.identifier.citedreferenceKeam B, Lee JH, Im SA, Yoon JH. Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy. J Natl Compr Cancer Netw 2011; 9: 465 â 477.
dc.identifier.citedreferenceYeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306 â 1311.
dc.identifier.citedreferenceLau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002; 99: 2324 â 2330.
dc.identifier.citedreferenceHsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, et al. A revisit of prophylactic lamivudine for chemotherapyâ associated hepatitis B reactivation in nonâ Hodgkin’s lymphoma: a randomized trial. Hepatology 2008; 47: 844 â 853.
dc.identifier.citedreferenceBarone M, Notarnicola A, Lopalco G, Viggiani MT, Sebastiani F, Covelli M, et al. Safety of longâ term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology 2015; 62: 40 â 46.
dc.identifier.citedreferenceVarisco V, Vigano M, Batticciotto A, Lampertico P, Marchesoni A, Gibertini P, et al. Low Risk of Hepatitis B Virus Reactivation in HBsAgâ negative/Antiâ HBcâ positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. J Rheumatol 2016; 43: 869 â 874.
dc.identifier.citedreferenceTamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAgâ positive and HBsAgâ negative cohorts. J Gastroenterol 2011; 46: 556 â 564.
dc.identifier.citedreferencePapa A, Felice C, Marzo M, Andrisani G, Armuzzi A, Covino M, et al. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with antiâ tumor necrosis factorâ alpha agents. J Crohns Colitis 2013; 7: 113 â 119.
dc.identifier.citedreferenceSeto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximabâ containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 2014; 32: 3736 â 3743.
dc.identifier.citedreferenceMasarone M, De Renzo A, La Mura V, Sasso FC, Romano M, Signoriello G, et al. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. BMC Gastroenterol 2014; 14: 31.
dc.identifier.citedreferenceZhang MY, Zhu GQ, Shi KQ, Zheng JN, Cheng Z, Zou ZL, et al. Systematic review with network metaâ analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapyâ induced hepatitis B virus reactivation. Oncotarget 2016; 7: 30642 â 30658.
dc.identifier.citedreferenceYang C, Qin B, Yuan Z, Chen L, Zhou HY. Metaâ analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation. Ann Hepatol 2016; 15: 501 â 511.
dc.identifier.citedreferenceYu S, Luo H, Pan M, Luis AP, Xiong Z, Shuai P, Zhang Z. Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a metaâ analysis. Int J Clin Pharm 2016; 38: 1035 â 1043.
dc.identifier.citedreferenceCerva C, Colagrossi L, Maffongelli G, Salpini R, Di Carlo D, Malagnino V, et al. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are antiâ HBcâ positive or HBVâ negative recipients with an antiâ HBcâ positive donor. Clin Microbiol Infect 2016; 22: 946.e1 â 946.e8.
dc.identifier.citedreferenceLiu WP, Wang XP, Zheng W, Ping LY, Zhang C, Wang GQ, et al. Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma. Leuk Lymphoma 2016; 57: 1355 â 1362.
dc.identifier.citedreferenceNakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, et al. Delayed HBV reactivation in rituximabâ containing chemotherapy: how long should we continue antiâ virus prophylaxis or monitoring HBVâ DNA? Leuk Res 2016; 50: 46 â 49.
dc.identifier.citedreferenceLenci I, Tisone G, Di Paolo D, Marcuccilli F, Tariciotti L, Ciotti M, et al. Safety of complete and sustained prophylaxis withdrawal in patients liverâ transplanted for HBVâ related cirrhosis at low risk of HBV recurrence. J Hepatol 2011; 55: 587 â 593.
dc.identifier.citedreferenceMorisco F, Castiglione F, Rispo A, Stroffolini T, Vitale R, Sansone S, et al. Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Dig Liver Dis 2011; 43 ( Suppl 1 ): S40 â S48.
dc.identifier.citedreferenceCho JH, Lim JH, Park GY, Kim JS, Kang YJ, Kwon O, et al. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection. Transpl Infect Dis 2014; 16: 295 â 303.
dc.identifier.citedreferenceHwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 2014; 11: 209 â 219.
dc.identifier.citedreferenceKondili LA, Osman H, Mutimer D. The use of lamivudine for patients with acute hepatitis B (a series of cases). J Viral Hepat 2004; 11: 427 â 431.
dc.identifier.citedreferenceTillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006; 13: 256 â 263.
dc.identifier.citedreferenceKumar M, Satapathy S, Monga R, Das K, Hissar S, Pande C, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007; 45: 97 â 101.
dc.identifier.citedreferenceSchmilovitzâ Weiss H, Melzer E, Turâ Kaspa R, Benâ Ari Z. Excellent outcome of Lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. J Clin Gastroenterol 2003; 37: 64 â 67.
dc.identifier.citedreferenceLok AS, Heattcote EJ, Hoofnagle JH. Management of hepatitis B: 2000â Summary of a Workshop. Gastroenterology 2001; 120: 1828 â 1853.
dc.identifier.citedreferenceChang TT, Chao YC, Gorbakov VV, Han KH, Gish RG, de Man R, et al. Results of up to 2 years of entecavir vs lamivudine therapy in nucleosideâ naive HBeAgâ positive patients with chronic hepatitis B. J Viral Hepat 2009; 16: 784 â 789.
dc.identifier.citedreferenceLiu Y, Miller MD, Kitrinos KM. Tenofovir alafenamide demonstrates broad crossâ genotype activity against wildâ type HBV clinical isolates and maintains susceptibility to drugâ resistant HBV isolates in vitro. Antiviral Res 2017; 139: 25 â 31.
dc.identifier.citedreferenceSheppardâ Law S, Zablotskaâ Manos I, Kermeen M, Holdaway S, Lee A, Zekry A, et al. Factors associated with HBV virological breakthrough. Antivir Ther 2017; 22: 53 â 60.
dc.identifier.citedreferenceTenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Longâ term monitoring shows hepatitis B virus resistance to entecavir in nucleosideâ naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503 â 1514.
dc.identifier.citedreferenceChung GE, Kim W, Lee KL, Hwang SY, Lee JH, Kim HY, et al. Addâ on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudineâ resistant chronic hepatitis B.[Erratum appears in Dig Dis Sci 2011 Aug;56(8):2509]. Dig Dis Sci 2011; 56: 2130 â 2136.
dc.identifier.citedreferenceHuang ZB, Zhao SS, Huang Y, Dai XH, Zhou RR, Yi PP, et al. Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudineâ resistant chronic hepatitis B: a systematic review and metaâ analysis. Clin Ther 2013; 35: 1997 â 2006.
dc.identifier.citedreferenceKim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. Rescue therapy for lamivudineâ resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir addâ on lamivudine combination therapy. J Gastroenterol Hepatol 2010; 25: 1374 â 1380.
dc.identifier.citedreferencePark JH, Jung SW, Park NH, Park BR, Kim MH, Kim CJ, et al. Efficacy of Tenofovirâ based Rescue Therapy in Lamivudineâ resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination. Clin Ther 2015; 37: 1433 â 1442.
dc.identifier.citedreferenceSuzuki Y, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, et al. Efficacy of entecavir treatment for lamivudineâ resistant hepatitis B over 3 years: histological improvement or entecavir resistance? J Gastroenterol Hepatol 2009; 24: 429 â 435.
dc.identifier.citedreferenceYim HJ, Seo YS, Yoon EL, Kim CW, Lee CD, Park SH, et al. Adding adefovir vs. switching to entecavir for lamivudineâ resistant chronic hepatitis B (ACE study): a 2â year followâ up randomized controlled trial. Liver Int 2013; 33: 244 â 254.
dc.identifier.citedreferenceSheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, et al. Selection of hepatitis B virus polymerase mutations in HIVâ coinfected patients treated with tenofovir. Antivir Ther 2005; 10: 727 â 734.
dc.identifier.citedreferenceFung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, et al. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5â year randomised study. J Hepatol 2017; 66: 11 â 18.
dc.identifier.citedreferenceBerg T, Zoulim F, Moeller B, Trinh H, Marcellin P, Chan S, et al. Longâ term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovirâ experienced chronic hepatitis B patients. J Hepatol 2014; 60: 715 â 722.
dc.identifier.citedreferencevan Bömmel F, de Man R, Wedemeyer H, Deterding K, Petersen J, Buggisch P, et al. Longâ term efficacy of tenofovir monotherapy for hepatitis B virusâ monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73 â 80.
dc.identifier.citedreferenceJang JW, Choi JY, Kim YS, Woo HY, Choi SK, Lee CH, et al. Longâ term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virusâ related cirrhosis. Hepatology 2015; 61: 1809 â 1820.
dc.identifier.citedreferencePeng CY, Chien RN, Liaw YF. Hepatitis B virusâ related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012; 57: 442 â 450.
dc.identifier.citedreferenceShim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Efficacy of entecavir in treatmentâ naive patients with hepatitis B virusâ related decompensated cirrhosis. J Hepatol 2010; 52: 176 â 182.
dc.identifier.citedreferenceKim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol 2014; 109: 1223 â 1233.
dc.identifier.citedreferencePapatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol 2015; 62: 363 â 370.
dc.identifier.citedreferenceSingal AK, Salameh H, Kuo YF, Fontana RJ. Metaâ analysis: the impact of oral antiâ viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2013; 38: 98 â 106.
dc.identifier.citedreferenceIacobellis A, Andriulli A. Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection. Expert Opin Pharmacother 2009; 10: 1929 â 1938.
dc.identifier.citedreferenceWang FY, Li B, Li Y, Liu H, Qu WD, Xu HW, et al. Entecavir for Patients with Hepatitis B Decompensated Cirrhosis in China: a metaâ analysis. Sci Rep 2016; 6: 32722.
dc.identifier.citedreferenceZhang X, Liu L, Zhang M, Gao S, Du Y, An Y, Chen S. The efficacy and safety of entecavir in patients with chronic hepatitis Bâ associated liver failure: a metaâ analysis. Ann Hepatol 2015; 14: 150 â 160.
dc.identifier.citedreferenceMiquel M, Nunez O, Traperoâ Marugan M, Diazâ Sanchez A, Jimenez M, Arenas J, Canos AP. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. Ann Hepatol 2013; 12: 205 â 212.
dc.identifier.citedreferenceYe XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: metaâ analysis. World J Gastroenterol 2013; 19: 6665 â 6678.
dc.identifier.citedreferenceCholongitas E, Papatheodoridis GV, Goulis J, Vlachogiannakos J, Karatapanis S, Ketikoglou J, et al. The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis. Ann Gastroenterol 2015; 28: 109 â 117.
dc.identifier.citedreferenceYueâ Meng W, Li YH, Wu HM, Yang J, Xu Y, Yang LH, Yang JH. Telbivudine versus lamivudine and entecavir for treatmentâ naive decompensated hepatitis B virusâ related cirrhosis. Clin Exp Med 2017; 17: 233 â 241.
dc.identifier.citedreferenceSingal AK, Fontana RJ. Metaâ analysis: oral antiâ viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther 2012; 35: 674 â 689.
dc.identifier.citedreferenceLiaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suetâ Hing Wong F, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62 â 72.
dc.identifier.citedreferenceLee SK, Song MJ, Kim SH, Lee BS, Lee TH, Kang YW, et al. Safety and efficacy of tenofovir in chronic hepatitis Bâ related decompensated cirrhosis. World J Gastroenterol 2017; 23: 2396 â 2403.
dc.identifier.citedreferencePark J, Jung KS, Lee HW, Kim BK, Kim SU, Kim DY, et al. Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virusâ Related Compensated and Decompensated Cirrhosis. Gut Liver 2017; 11: 828 â 834.
dc.identifier.citedreferenceLange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, Sarrazin C. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001 â 2006.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hep29800.pdf
Size:
557.7KB
Format:
PDF
View/Open
Name:
hep29800_am.pdf
Size:
772.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.